Caxton Associates LLP Sells 259,388 Shares of 10x Genomics $TXG

Caxton Associates LLP cut its position in shares of 10x Genomics (NASDAQ:TXG) by 74.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,406 shares of the company’s stock after selling 259,388 shares during the period. Caxton Associates LLP’s holdings in 10x Genomics were worth $1,012,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TXG. Amundi increased its position in shares of 10x Genomics by 16,013.7% during the first quarter. Amundi now owns 320,340 shares of the company’s stock worth $2,553,000 after purchasing an additional 318,352 shares in the last quarter. Jump Financial LLC boosted its position in shares of 10x Genomics by 130.2% in the 2nd quarter. Jump Financial LLC now owns 1,041,051 shares of the company’s stock worth $12,055,000 after purchasing an additional 588,769 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in 10x Genomics by 163.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company’s stock worth $5,634,000 after buying an additional 400,430 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in 10x Genomics by 235.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after buying an additional 4,987,195 shares in the last quarter. Finally, Pallas Capital Advisors LLC raised its stake in 10x Genomics by 138.8% in the second quarter. Pallas Capital Advisors LLC now owns 56,776 shares of the company’s stock valued at $657,000 after buying an additional 32,996 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TXG. Wall Street Zen lowered 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research note on Monday, December 8th. Morgan Stanley restated an “equal weight” rating and set a $20.00 price target (up previously from $17.00) on shares of 10x Genomics in a research note on Monday, December 1st. UBS Group raised their price target on shares of 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Finally, Piper Sandler boosted their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $15.73.

Insider Transactions at 10x Genomics

In related news, CFO Adam Taich sold 11,888 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $225,872.00. Following the sale, the chief financial officer directly owned 297,385 shares of the company’s stock, valued at approximately $5,650,315. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Serge Saxonov sold 13,261 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $251,959.00. Following the sale, the chief executive officer owned 1,021,556 shares in the company, valued at approximately $19,409,564. This represents a 1.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 33,432 shares of company stock valued at $635,208 in the last 90 days. 10.03% of the stock is currently owned by company insiders.

10x Genomics Stock Performance

NASDAQ TXG opened at $15.76 on Tuesday. The firm has a market capitalization of $1.99 billion, a P/E ratio of -25.42 and a beta of 2.14. The stock has a 50-day simple moving average of $15.13 and a two-hundred day simple moving average of $13.37. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $20.34.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. The firm had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.The company’s revenue was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.30) earnings per share. As a group, analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.